Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered
into this study at approximately 26 centers in the United States. This study aims to evaluate
the safety and efficacy of sevelamer carbonate powder dosed once-a-day (QD) with the largest
meal compared to sevelamer hydrochloride tablets dosed three-times-per-day (TID) with meals.
The total length of participation is approximately 24 weeks.